170 related articles for article (PubMed ID: 36113085)
1. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
Tran TB; Downing L; Elmes JB; Arnall JR; Moore DC
J Pharm Pract; 2024 Feb; 37(1):184-189. PubMed ID: 36113085
[No Abstract] [Full Text] [Related]
2. Avatrombopag: A Review in Thrombocytopenia.
Markham A
Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
[TBL] [Abstract][Full Text] [Related]
3. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of avatrombopag for the treatment of thrombocytopenia.
Virk ZM; Kuter DJ; Al-Samkari H
Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
[No Abstract] [Full Text] [Related]
5. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
[TBL] [Abstract][Full Text] [Related]
6. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
Xu H; Cai R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
[No Abstract] [Full Text] [Related]
7. Avatrombopag for the treatment of immune thrombocytopenia.
Długosz-Danecka M; Zdziarska J; Jurczak W
Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
[TBL] [Abstract][Full Text] [Related]
8. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
9. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
Kuter DJ; Allen LF
Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
11. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
[TBL] [Abstract][Full Text] [Related]
13. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
Cheloff AZ; Al-Samkari H
J Blood Med; 2019; 10():313-321. PubMed ID: 31565009
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
15. Avatrombopag: First Global Approval.
Shirley M
Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
[TBL] [Abstract][Full Text] [Related]
16. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.
Al-Samkari H
Drugs Today (Barc); 2018 Nov; 54(11):647-655. PubMed ID: 30539164
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
Al-Samkari H; Nagalla S
Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
[TBL] [Abstract][Full Text] [Related]
19. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Maan R; de Knegt RJ; Veldt BJ
Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
[TBL] [Abstract][Full Text] [Related]
20. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
[No Abstract] [Full Text] [Related]
[Next] [New Search]